BTX Brooklyn ImmunoTherapeutics Inc

Price (delayed)

$9.01

Market cap

$466.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$419.55M

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The ...

Highlights
BTX's gross profit has dropped by 76% year-on-year
The company's revenue has shrunk by 73% YoY

Key stats

What are the main financial stats of BTX
Market
Shares outstanding
51.73M
Market cap
$466.08M
Enterprise value
$419.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.64
Price to sales (P/S)
144.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
158.2
Earnings
Revenue
$2.65M
EBIT
-$28.83M
EBITDA
-$27.91M
Free cash flow
-$11.79M
Per share
EPS
-$1.66
Free cash flow per share
-$0.28
Book value per share
$0.85
Revenue per share
$0.06
TBVPS
$1.48
Balance sheet
Total assets
$64.71M
Total liabilities
$29.53M
Debt
$3.63M
Equity
$35.18M
Working capital
$44.26M
Liquidity
Debt to equity
0.1
Current ratio
6.76
Quick ratio
6.53
Net debt/EBITDA
1.67
Margins
EBITDA margin
-1,052.2%
Gross margin
49.3%
Net margin
-1,092.1%
Operating margin
-354.1%
Efficiency
Return on assets
-111.2%
Return on equity
-589.1%
Return on invested capital
-385.9%
Return on capital employed
-50.5%
Return on sales
-1,086.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTX stock price

How has the Brooklyn ImmunoTherapeutics stock price performed over time
Intraday
-6.34%
1 week
-1.53%
1 month
-7.4%
1 year
89.29%
YTD
101.12%
QTD
-3.12%

Financial performance

How have Brooklyn ImmunoTherapeutics's revenue and profit performed over time
Revenue
$2.65M
Gross profit
$1.31M
Operating income
-$9.39M
Net income
-$28.96M
Gross margin
49.3%
Net margin
-1,092.1%
The operating income has shrunk by 106% YoY
BTX's gross profit has dropped by 76% year-on-year
The company's revenue has shrunk by 73% YoY
The net margin is down by 39% QoQ

Growth

What is Brooklyn ImmunoTherapeutics's growth rate over time

Valuation

What is Brooklyn ImmunoTherapeutics stock price valuation
P/E
N/A
P/B
10.64
P/S
144.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
158.2
Brooklyn ImmunoTherapeutics's EPS has decreased by 26% YoY and by 8% from the previous quarter
BTX's P/B is 180% above its 5-year quarterly average of 3.8
The P/S is 75% higher than the last 4 quarters average of 82.3
The company's revenue has shrunk by 73% YoY

Efficiency

How efficient is Brooklyn ImmunoTherapeutics business performance
The ROA has plunged by 177% YoY but it has grown by 38% from the previous quarter
Brooklyn ImmunoTherapeutics's ROS has decreased by 39% from the previous quarter
The company's return on invested capital fell by 13% QoQ

Dividends

What is BTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTX.

Financial health

How did Brooklyn ImmunoTherapeutics financials performed over time
Brooklyn ImmunoTherapeutics's total assets is 119% higher than its total liabilities
BTX's total liabilities is up by 18% since the previous quarter
The debt is 90% lower than the equity
The debt to equity has soared by 116% from the previous quarter but it has plunged by 94% YoY
The debt is up by 28% QoQ and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.